Eli Lilly Announces Phase 3 TRAILBLAZER-ALZ 2 Trial Results

Eli Lilly and Company Shows Strong Fundamentals Amid Market Volatility

Eli Lilly and Company (NYSE: LLY) has emerged as a compelling investment opportunity, particularly for investors seeking fundamentally strong stocks that are currently oversold. Recent developments in the company's Alzheimer’s disease research have further bolstered its long-term value proposition.

On July 30, the company released results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study, which demonstrated that patients treated with Kisunla (donanemab-azbt) experienced a slower decline in cognitive function compared to an untreated group from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The benefits observed were not only significant but also continued to improve over a three-year period, underscoring the potential of early intervention in managing this debilitating condition.

The TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original trial, designed to evaluate the efficacy and safety of Kisunla in individuals with early symptomatic Alzheimer’s disease. Participants who had initially received Kisunla either continued the treatment or were switched to a placebo. Those who started on a placebo were later given Kisunla in a blinded manner, ensuring the integrity of the study’s findings.

One of the key outcomes of the study was the reduction in the risk of progression to the next stage of the disease by 27% on the Clinical Dementia Rating-Global Score (CDR-G) when Kisunla was initiated earlier. This finding highlights the importance of timely treatment in slowing the progression of Alzheimer’s, offering hope to millions of patients and their families.

In addition to its advancements in Alzheimer’s research, Eli Lilly has also shown strong financial performance. In Q2 2025, the company reported net income of $5.66 billion and earnings per share (EPS) of $6.29, compared to net income of $2.97 billion and EPS of $3.28 in Q2 2024. Both quarters included acquired IPR&D charges of $0.14 per share, indicating the company's ongoing commitment to innovation and development.

Despite these positive developments, Eli Lilly’s stock faced some challenges during the quarter. The company missed earnings expectations and encountered heightened scrutiny around GLP-1 pricing dynamics. However, sales of Mounjaro and Zepbound saw significant growth, with Mounjaro revenue reaching $3.8 billion and Zepbound hitting $2.3 billion in revenue.

Market reactions to news about certain payers shifting GLP-1 drugs off preferred formularies raised concerns about future prescription growth. While demand for these drugs remains robust, competitive dynamics and manufacturing constraints led to investor caution. Volatility in the broader weight-loss drug space also contributed to relative weakness in the stock.

Despite short-term pricing concerns, Eli Lilly is well-positioned for multi-year growth. Its leadership in obesity and diabetes treatments, combined with a promising late-stage pipeline in Alzheimer’s, immunology, and oncology, offers significant upside potential.

While Eli Lilly presents a compelling case for long-term investment, some investors may find greater promise in the AI sector. Several AI stocks are seen as having higher return potential with limited downside risk. For those interested in exploring such opportunities, there are reports highlighting the cheapest AI stocks with substantial growth potential.

For more insights into investment opportunities, consider exploring the following:

• 13 Cheap AI Stocks to Buy According to Analysts
• 11 Unstoppable Growth Stocks to Invest in Now

Investors should carefully evaluate their options and consider their risk tolerance before making any investment decisions.